LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027

LB PHARMACEUTICALS INC

Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.
Investors include Balyasny, Caligan, Commodore, Deep Track, Nantahala, Pivotal, Spruce Street, TCGX, Trails Edge.
Net proceeds to fund Phase 2 trial of LB-102 as adjunctive MDD treatment and for working capital.
Phase 2 trial: 380 patients, 50 sites U.S./Europe, randomized 1:1 vs placebo, primary endpoint MADRS-10 at week 6.
Trial to start early 2027; topline results expected first half 2029.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LB PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain investors valued at approximately $100.0 million (effective 2026-02-04).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: approximately $100.0 million
Effective: 2026-02-04

Exact text from the filing

On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,417,107 shares of Common Stock

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-038539

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.